Tardive dyskinesia and new antipsychotics

@article{Correll2008TardiveDA,
  title={Tardive dyskinesia and new antipsychotics},
  author={Christoph U. Correll and Eva M Schenk},
  journal={Current Opinion in Psychiatry},
  year={2008},
  volume={21},
  pages={151–156}
}
Purpose of review To provide an update on tardive dyskinesia rates in patients treated with first-generation or second-generation antipsychotics in studies published since the last systematic review in 2004. Recent findings Across 12 trials (n = 28 051, age 39.7 years, 59.7% male, 70.9% white, followed for 463 925 person-years), the annualized tardive dyskinesia incidence was 3.9% for second-generation antipsychotics and 5.5% for first-generation antipsychotics. Stratified by age, annual… Expand
View on Wolters Kluwer
documentforsafety.org
234 Citations
Highly Influential Citations
6
Background Citations
56
Methods Citations
2
Results Citations
11

234 Citations

Citation Type

Citation Type

Tardive Dyskinesia and Tardive Dystonia With Second-Generation Antipsychotics in Non-Elderly Schizophrenic Patients Unexposed to First-Generation Antipsychotics: A Cross-Sectional and Retrospective Study
TLDR
It is indicated that more clinical attention and research efforts are needed regarding SGA-associated tardive movement syndromes, including a larger-scale prevalence assessment, after the first to indicate that a comorbid obsessive-compulsive syndrome might be an associated factor of tardives movement syndrome. Expand
Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting.
TLDR
The observed rate of tardive dyskinesia represents a real world estimate of the risk of TD with atypical antipsychotic agents in patients with mood disorders, and with early recognition symptoms appear to be reversible and further treatment with another atypicals does not necessarily lead to relapse. Expand
Tardive dyskinesia and other movement disorders secondary to aripiprazole
The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical… Expand
Covert Dyskinesia With Aripiprazole
TLDR
Litigation to date suggests that APZ is the atypical antipsychotic most commonly reported with CD, and a possible risk might be APZ's unique mechanism of action and its association with akathisia. Expand
Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics
TLDR
There are significant differences in the prevalence and clinical correlates of tardive dyskinesia in schizophrenia treated with clozapine versus typical antipsychotics. Expand
Tardive and spontaneous dyskinesia incidence in the general population
TLDR
Diabetes, psychoses, and especially schizophrenia are positively associated with SD and TD, with persons with schizophrenia having 4.4 times greater risk of SD than those without the disease. Expand
Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients
TLDR
This review will discuss the evidence for a number of medications of several different classes that have been studied for the treatment of TD since the 1970s with an emphasis on placebo controlled trials when possible and suggest the use of atypical versus conventional antipsychotics whenever possible. Expand
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
TLDR
The study demonstrated high prevalence of tardive dyskinesia, and the annual incidence comparable to the results of a meta-analysis by Corell et al., and the use of antipsychotics in polytherapy more than tripled the risk of tARDive dysKinesia. Expand
Tardive Dyskinesia: Treatment Update
Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of… Expand
Use of aripiprazole in tardive dyskinesia: An open label study of six cases
TLDR
It is supported that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
TLDR
Results from 11 long-term studies support the idea that second- generation antipsychotics have a reduced risk for tardive dyskinesia, compared to first-generation antipsychotic, although the doses of haloperidol used in the comparator studies were relatively high. Expand
One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.
  • C. Correll, J. Kane
  • Psychology, Medicine
  • Journal of child and adolescent psychopharmacology
  • 2007
TLDR
Results across 10 studies suggest relatively low 1-year TD rates in pediatric patients treated with SGAs, which may have obscured a potentially greater risk for TD in children and adolescents treated with higher total SGA doses and for longer durations. Expand
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
TLDR
The results suggest that the relative advantage of second-generation antipsychotics in terms of lower rates of incidence and persistence of tardive dyskinesia, observed in technical randomized controlled trials, generalizes to routine clinical care. Expand
Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
TLDR
Tardive dyskinesia rates for patients beginning treatment with conventional antipsychotics in their fifth decade or later are three to five times what has been found for younger patients, despite treatment with lower doses. Expand
The effect of atypical versus typical antipsychotics on tardive dyskinesia
  • J. Leon
  • Medicine
  • European Archives of Psychiatry and Clinical Neuroscience
  • 2006
TLDR
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and naturalistic design, relatively small samples in the first two groups, and lack of information on the duration of the atypicals. Expand
The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.
  • J. de Leon
  • Medicine
  • European archives of psychiatry and clinical neuroscience
  • 2007
TLDR
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and the lack of information on the duration of the atypicals and their relatively recent introduction to the market. Expand
Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.
TLDR
The risk of tardive dyskinesia in older outpatients is high, even with relatively short treatment with low doses of conventional neuroleptics. Expand
Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course
TLDR
The findings support the view that tardive dyskinesia is a dynamic phenomenon, is only partly drug-induced, has a mild course during treatment with modern neuroleptics, and appears to have some correlation with mental slowness. Expand
Prospective study of tardive dyskinesia incidence in the elderly.
TLDR
Investigation of the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs found psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardiv dyskine vulnerability. Expand
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
TLDR
Patients in the first 5 years of exposure to persistent TD could be targeted for prevention programs if resources are limited and differences in incidence across studies may be explained in terms of patient characteristics and other methodological factors. Expand
...
1
2
3
4
5
...